MA28241A1 - Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer - Google Patents

Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer

Info

Publication number
MA28241A1
MA28241A1 MA29143A MA29143A MA28241A1 MA 28241 A1 MA28241 A1 MA 28241A1 MA 29143 A MA29143 A MA 29143A MA 29143 A MA29143 A MA 29143A MA 28241 A1 MA28241 A1 MA 28241A1
Authority
MA
Morocco
Prior art keywords
disease
treatment
alzheimer
hydroxyethylamine
tricyclic
Prior art date
Application number
MA29143A
Other languages
English (en)
Inventor
Emmanuel Hubert Demont
Sally Redshaw
David R Vesey
Daryl Simon Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28241A1 publication Critical patent/MA28241A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVES TRICYCLIQUES D¿HYDROXYETHYLAMINE A NOYAU INDOLE ET LEUR UTILISATION DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER La présente invention concerne des dérivés d'hydroxyethylamine nouveaux ayant une activité inhibitrice de Asp2 ((béta)-sécrétase, BACE1 ou mémapsine), des procédés pour leur préparation, des compositions les contenant et leur utilisation dans le traitement de maladies caractérisées par des taux élevés de (béta)-amyloïde ou des dépôts de (béta)-amyloïde, en particulier la maladie d'Alzheimer.
MA29143A 2003-12-12 2006-06-26 Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer MA28241A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0328900.6A GB0328900D0 (en) 2003-12-12 2003-12-12 Novel compounds

Publications (1)

Publication Number Publication Date
MA28241A1 true MA28241A1 (fr) 2006-10-02

Family

ID=30130158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29143A MA28241A1 (fr) 2003-12-12 2006-06-26 Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer

Country Status (17)

Country Link
US (1) US20070073060A1 (fr)
EP (1) EP1692143B1 (fr)
JP (1) JP2007513913A (fr)
KR (1) KR20060121164A (fr)
CN (1) CN1914214A (fr)
AT (1) ATE414090T1 (fr)
AU (1) AU2004299231A1 (fr)
BR (1) BRPI0417476A (fr)
CA (1) CA2549072A1 (fr)
DE (1) DE602004017777D1 (fr)
GB (1) GB0328900D0 (fr)
IL (1) IL175819A0 (fr)
IS (1) IS8521A (fr)
MA (1) MA28241A1 (fr)
NO (1) NO20063137L (fr)
RU (1) RU2006124863A (fr)
WO (1) WO2005058915A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
BRPI0515383A (pt) * 2004-09-21 2008-07-22 Pfizer Prod Inc n-etil hidroxietilamina útil no tratamento de condições do snc
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2007047305A1 (fr) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Procedes de traitement de l'amyloïdose en utilisant des derives de cyclopropyle inhibiteurs de l'aspartyle-protease
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
NZ582871A (en) * 2007-07-27 2011-09-30 Sanofi Aventis 1,2,3,4-Tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5- tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof
NZ588715A (en) * 2008-05-29 2012-11-30 Albany Molecular Res Inc 5-ht3 receptor modulators, methods of making, and use thereof
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
BR112015003824B1 (pt) * 2012-08-24 2022-10-04 Treventis Corporation Composto, composição farmacêutica e uso do composto
WO2019075358A1 (fr) * 2017-10-13 2019-04-18 Ghosh Arun K Inhibiteurs de bace1 pour le traitement de la maladie d'alzheimer
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033795A1 (fr) * 1997-02-04 1998-08-06 The Regents Of The University Of California Inhibiteurs de cathepsine d nanomolaires et non peptidiques
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
EP1299352B1 (fr) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Composes pour traiter la maladie d'alzheimer
US7176242B2 (en) * 2001-11-08 2007-02-13 Elan Pharmaceuticals, Inc. N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
GB0328900D0 (en) 2004-01-14
JP2007513913A (ja) 2007-05-31
ATE414090T1 (de) 2008-11-15
DE602004017777D1 (de) 2008-12-24
US20070073060A1 (en) 2007-03-29
RU2006124863A (ru) 2008-01-20
IS8521A (is) 2006-06-26
EP1692143B1 (fr) 2008-11-12
CN1914214A (zh) 2007-02-14
BRPI0417476A (pt) 2007-05-08
CA2549072A1 (fr) 2005-06-30
EP1692143A1 (fr) 2006-08-23
WO2005058915A1 (fr) 2005-06-30
KR20060121164A (ko) 2006-11-28
IL175819A0 (en) 2006-10-05
AU2004299231A1 (en) 2005-06-30
NO20063137L (no) 2006-08-31

Similar Documents

Publication Publication Date Title
MA28241A1 (fr) Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
MA27608A1 (fr) Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
WO2004080376A3 (fr) Nouveaux composes
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer